Encision Inc. filings document the company’s Exchange Act reporting status, common-stock registration matters, and material corporate events. The Form 15-12G records Encision’s certification and notice to terminate registration under Section 12(g) and suspend reporting duties for its common stock.
Recent Form 8-K disclosures cover the company’s plan to deregister, its OTC-traded common stock, board and executive changes, and related exhibit filings. The filing record also identifies Encision as a Colorado issuer with common stock, no par value, under the ECIA trading symbol.
ENCISION INC (ECIA) filed a Form D notice for a Regulation D exempt offering of equity securities under Rule 506(b). This is a new notice, with the first sale reported on September 8, 2026.
The company reports that it has sold $80,000 of equity in this offering, with $0 remaining to be sold, indicating the offering is fully subscribed as described. ENCISION INC lists its revenue range as $5,000,001–$25,000,000 and identifies its industry group as health care/biotechnology. No sales commissions or finders’ fees were paid, and the filing does not allocate offering proceeds to executives or directors.
ENCISION INC CEO and director Robert H. Fries reported buying additional common stock in two recent open-market transactions. On April 15, 2026, he purchased 155,535 shares at $0.14 per share. On April 16, 2026, he bought a further 11,250 shares at $0.20 per share. Following these purchases, he directly holds 1,506,785 shares of ENCISION INC common stock.
Encision Inc. plans to deregister its common stock and stop filing regular reports with the SEC. The company announced that it intends to file a Form 15, which will start the deregistration process for its common stock.
The deregistration is expected to become effective ninety days after the Form 15 is filed. Once effective, Encision will suspend its ongoing reporting obligations, meaning investors will no longer receive quarterly and annual SEC filings. The company’s decision was disclosed in a current report and related press release.
Encision, Inc. announced that Gregory Trudel resigned from its board of directors and also stepped down as CEO, President and executive officer effective December 8, 2025. The company states that Mr. Trudel disagreed with the other board members on the future direction of the company and concluded it was best to resign, while emphasizing that, apart from this difference over future direction, his resignation did not stem from any dispute over current operations, policies or practices.
Following his departure, the board appointed long-time director Robert H. Fries as Interim President and CEO. Mr. Fries, age 77, has served on Encision’s board since 2003, is a certified public accountant (inactive), and has extensive finance and tax consulting experience with large public multinational companies, which the company cites as qualifications for his interim leadership role.